ArticleWorld journal of gastroenterology2007
NCB-02 (standardized Curcumin preparation) protects dinitrochlorobenzene- induced colitis through down-regulation of NFkappa-B and iNOS.
Article in World journal of gastroenterology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 72 citations in OpenAlex.
- Evaluation of oral nano-curcumin formulation effectiveness in patients with mild to moderate ulcerative colitis: a randomized, placebo-controlled, double-blind clinical trial.Naunyn-Schmiedeberg's archives of pharmacology · 2026Trial
- Effectiveness of curcumin in achieving clinical remission and reducing disease activity in ulcerative colitis: a randomised, controlled trial.Przeglad gastroenterologiczny · 2026Article
- Curcumin for inflammatory bowel disease therapy: advances in mechanisms, clinical applications, and drug delivery.Archives of pharmacal research · 2025Review
- Oral enzyme-responsive nanoprobes for targeted theranostics of inflammatory bowel disease.Journal of nanobiotechnology · 2024Article
- Phytochemicals and Regulation of NF-kB in Inflammatory Bowel Diseases: An Overview of In Vitro and In Vivo Effects.Metabolites · 2023Review
- Curcumin and Its Modified Formulations on Inflammatory Bowel Disease (IBD): The Story So Far and Future Outlook.Pharmaceutics · 2021Review
- Curcumin suppresses intestinal microvascular endothelial cells invasion and angiogenesis induced by activated platelets.Experimental and therapeutic medicine · 2019Article
- Curcumin and Intestinal Inflammatory Diseases: Molecular Mechanisms of Protection.International journal of molecular sciences · 2019Review
- Phytotherapies in inflammatory bowel disease.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2019Review
- Biodistribution and targeting potential assessment of mucoadhesive chitosan nanoparticles designed for ulcerative colitisRSC advances · 2018Article
- Of mice and men: a novel dietary supplement for the treatment of ulcerative colitis.Therapeutic advances in gastroenterology · 2018Article
- Curcumin half analog modulates interleukin-6 and tumor necrosis factor-alpha in inflammatory bowel disease.Pharmacognosy magazine · 2015Article
- Botanical Drugs as an Emerging Strategy in Inflammatory Bowel Disease: A Review.Mediators of inflammation · 2015Review
- Dietary agents and phytochemicals in the prevention and treatment of experimental ulcerative colitis.Journal of traditional and complementary medicine · 2014Review
- Naringin ameliorates acetic acid induced colitis through modulation of endogenous oxido-nitrosative balance and DNA damage in rats.Journal of biomedical research · 2014Article
- Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers.British journal of pharmacology · 2013Review
- A neutraceutical by design: the clinical application of curcumin in colonic inflammation and cancer.Scientifica · 2012Review
- Bone, inflammation, and inflammatory bowel disease.Current osteoporosis reports · 2011Review
- Topological virtual screening: a way to find new compounds active in ulcerative colitis by inhibiting NF-κB.Molecular diversity · 2011Article
- Therapeutic potential of curcumin in gastrointestinal diseases.World journal of gastrointestinal pathophysiology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo evaluate the efficacy and mechanism of action of NCB 02, a standardized Curcumin preparation, against 2, 4 dinitrochlorobenzene (DNCB) induced ulcerative colitis in rats.
methodsUlcerative colitis was induced in male rats by sensitizing with topical application of DNCB in acetone for 14 d and intra-colonol challenge with DNCB on day 15. A separate group of animals with vehicle treatment in similar fashion served as control group. Colitis rats were divided into different groups and treated with NCB-02 at doses of 25, 50 and 100 mg/kg b.wt p.o. for 10 d. Sulfasalazine at a dose of 100 mg/kg b.wt for 10 d served as a reference group. On day 10 after respective assigned treatment, all the animals were euthanized and the length of the colon, weight of entire colon and distal 8 cm of the colon were recorded. The distal part of the colon was immediately observed under a stereomicroscope and the degree of damage was scored. Further distal 8 cm of the colon was subject to the determination of colonic myeloperoxidase (MPO), lipid peroxidation (LPO) and alkaline phosphatase (ALP) activities. A small piece of the sample from distal colon of each animal was fixed in 10% neutral buffered formalin and embedded in paraffin wax and sectioned for immunohistochemical examination of NFkappa-B and iNOS expression.
resultsNCB-02 showed a dose dependent protection against DNCB-induced alteration in colon length and weight. NCB-02 treatment also showed a dose dependent protection against the elevated levels of MPO, LPO and ALP, induced by DNCB. NCB-02 demonstrated a significant effect at a dose of 100 mg/kg b.wt., which was almost equipotent to 100 mg/kg b.wt. of sulfasalazine. Treatment with sulfasalazine and curcumin at a dose of 100 mg/kg b.wt. inhibited the DNCB-induced overexpression of NFkappa-B and iNOS in the colon.
conclusionCurcumin treatment ameliorates colonic damage in DNCB induced colitic rats, an effect associated with an improvement in intestinal oxidative stress and downregulation of colonic NFkappa-B and iNOS expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.